Gland Pharma has announced a schedule of analyst and institutional investor meetings for September 2026. The company disclosed the engagement calendar on September 10, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting schedule

The upcoming engagements include one-on-one meetings with specific investors and a group session. The schedule is subject to change due to exigencies on the part of the investor, analyst, or company.

Regulatory disclosure

The company issued the intimation to BSE Limited and National Stock Exchange of India Limited. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the disclosure. The registered office is located in Hyderabad, Telangana.

Gland Pharma promoter Fosun Pharma Industrial Pte. Ltd. has disposed of 98,97,000 equity shares, representing 6.00% of the company’s voting capital, through an open market transaction executed on September 4, 2026.

Transaction details

The disposal was disclosed to stock exchanges on September 8, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The sale reduces Fosun Pharma’s holding from 51.76% to 45.76%.

Shareholding pattern

Prior to the transaction, Fosun Pharma held 8,53,93,894 shares, constituting 51.76% of the total share/voting capital and 51.36% of the diluted share/voting capital. Following the sale, its holding stands at 7,54,96,894 shares, or 45.76% of the voting capital and 45.41% of the diluted capital.

The total equity share capital of Gland Pharma remained unchanged at 1,64,966,661 equity shares of ₹1 each. The total diluted share/voting capital is 1,66,262,312 equity shares of ₹1 each.

No shares were encumbered with pledge, lien, or non-disposal undertaking before or after the transaction.